Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Collaboration with Soane BioSciences is intended to build on PE's technologies in fluorescent electrophoresis, reagents, software and systems via integration with Hayward, California-based Soane's technologies in microfluidic chips and analysis methods "to create highly automated and integrated genetic analysis systems," the companies announce May 19. "Microfluidic systems offer the potential to significantly reduce separation time, increase throughput, provide greater integration of sample preparation and analysis steps, and deliver enhanced automation," Soane CEO Joseph Limber comments. Under the agreement, Soane will manufacture and supply PE with microfluidic chips for product development and exclusive worldwide marketing rights. PE is also making an equity investment in privately held Soane. Financial details of the deal are not being disclosed. On May 10, PE reported the formation of an 80/20 joint venture with The Institute for Genomic Research that will use PE's Model 3700 ultra-high throughput analyzer to complete the sequencing of the human genome's 3 bil. base pairs in three years ("The Gray Sheet" May 18, p. 15)

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts